Drugs / DP-VPA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00640965 | Jul 2008 → Jun 2009 | migraine disorder | D-Pharm Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DP-VPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00640965 ↗ |
| Route | Oral | “Active and placebo will be administered orally and once-daily on an add-on basis” NCT00640965 ↗ |